JP2003508388A5 - - Google Patents

Download PDF

Info

Publication number
JP2003508388A5
JP2003508388A5 JP2001519682A JP2001519682A JP2003508388A5 JP 2003508388 A5 JP2003508388 A5 JP 2003508388A5 JP 2001519682 A JP2001519682 A JP 2001519682A JP 2001519682 A JP2001519682 A JP 2001519682A JP 2003508388 A5 JP2003508388 A5 JP 2003508388A5
Authority
JP
Japan
Prior art keywords
unsubstituted
group
substituted
alkyl
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001519682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003508388A (ja
JP4831906B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/023556 external-priority patent/WO2001016114A2/en
Publication of JP2003508388A publication Critical patent/JP2003508388A/ja
Publication of JP2003508388A5 publication Critical patent/JP2003508388A5/ja
Application granted granted Critical
Publication of JP4831906B2 publication Critical patent/JP4831906B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001519682A 1999-08-27 2000-08-25 Cxcr3機能を調節するための複素環式化合物および方法 Expired - Fee Related JP4831906B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15121299P 1999-08-27 1999-08-27
US60/151,212 1999-08-27
PCT/US2000/023556 WO2001016114A2 (en) 1999-08-27 2000-08-25 Heterocyclic compounds and methods for modulating cxcr3 function

Publications (3)

Publication Number Publication Date
JP2003508388A JP2003508388A (ja) 2003-03-04
JP2003508388A5 true JP2003508388A5 (US07794700-20100914-C00152.png) 2007-08-30
JP4831906B2 JP4831906B2 (ja) 2011-12-07

Family

ID=22537783

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001519682A Expired - Fee Related JP4831906B2 (ja) 1999-08-27 2000-08-25 Cxcr3機能を調節するための複素環式化合物および方法

Country Status (8)

Country Link
US (3) US6559160B1 (US07794700-20100914-C00152.png)
EP (1) EP1216232B1 (US07794700-20100914-C00152.png)
JP (1) JP4831906B2 (US07794700-20100914-C00152.png)
AT (1) ATE342257T1 (US07794700-20100914-C00152.png)
AU (1) AU7080500A (US07794700-20100914-C00152.png)
DE (1) DE60031285T2 (US07794700-20100914-C00152.png)
ES (1) ES2272319T3 (US07794700-20100914-C00152.png)
WO (1) WO2001016114A2 (US07794700-20100914-C00152.png)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070021493A1 (en) 1999-09-16 2007-01-25 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7671200B2 (en) * 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
US8852937B2 (en) 2000-03-30 2014-10-07 Curis, Inc. Small organic molecule regulators of cell proliferation
EA007538B1 (ru) 2000-12-11 2006-10-27 Туларик Инк. Антагонисты cxcr3
US6469002B1 (en) * 2001-04-19 2002-10-22 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
WO2003018549A2 (en) * 2001-08-30 2003-03-06 Chemocentryx, Inc. Bicyclic compounds as inhibitors of chemokine binding to us28
ATE469648T1 (de) 2001-09-05 2010-06-15 Minerva Biotechnologies Corp Zusammensetzungen und deren verwendung zur behandlung von krebs
US6753428B2 (en) * 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
AU2003213092A1 (en) * 2002-02-15 2003-09-09 Smithkline Beecham Corporation Syntheses of quinazolinones
US20080070864A1 (en) 2002-03-07 2008-03-20 X-Ceptor Therapeutics, Inc. Quinazolinone Modulators Of Nuclear Receptors
US7381730B2 (en) * 2002-03-15 2008-06-03 Bristol-Myers Squibb Company 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
AU2003236354A1 (en) * 2002-04-03 2003-10-13 Sumitomo Pharmaceuticals Co., Ltd. Novel blood sugar controller and method of screening the same
WO2003084544A2 (en) * 2002-04-04 2003-10-16 Cv Therapeutics, Inc. Compounds dor increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis
US20030225288A1 (en) * 2002-04-12 2003-12-04 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
BR0309278A (pt) * 2002-04-17 2005-04-26 Cytokinetics Inc Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
CA2485148A1 (en) * 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
AU2003270015A1 (en) * 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003265242A1 (en) * 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
EP2399903A1 (en) * 2002-05-24 2011-12-28 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
EP1556357A4 (en) * 2002-06-14 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
US6949538B2 (en) 2002-07-17 2005-09-27 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003256805A1 (en) * 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
EP1539180A4 (en) * 2002-08-21 2006-08-30 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
WO2004024086A2 (en) * 2002-09-13 2004-03-25 Cytokinetics, Inc. Compounds, compositions and methods
AU2003277079A1 (en) * 2002-09-30 2004-05-04 Cytokinetics, Inc. Compounds, compositions, and methods
MXPA05003607A (es) * 2002-10-04 2005-11-17 Prana Biotechnology Ltd Compuestos neurologicamente activos.
EP1608317B1 (en) * 2003-03-25 2012-09-26 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2004092123A2 (en) * 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
EP1670456A2 (en) * 2003-10-06 2006-06-21 Cytokinetics, Inc. Compounds, compositions and methods
US20050197327A1 (en) * 2003-11-03 2005-09-08 Gustave Bergnes Compounds, compositions, and methods
US20050148593A1 (en) * 2003-11-07 2005-07-07 Gustave Bergnes Compounds, compositions, and methods
US7439254B2 (en) * 2003-12-08 2008-10-21 Cytokinetics, Inc. Compounds, compositions, and methods
JP4452839B2 (ja) * 2004-03-09 2010-04-21 国立大学法人京都大学 Cxcr3阻害剤を含有する医薬組成物
DK1737831T3 (da) 2004-04-02 2013-08-19 Prana Biotechnology Ltd Neurologisk aktive forbindelser
US7375102B2 (en) * 2004-06-28 2008-05-20 Amgen Sf, Llc Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
US7939538B2 (en) * 2004-06-28 2011-05-10 Amgen Inc. Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
WO2006026597A2 (en) * 2004-08-30 2006-03-09 Smithkline Beecham Corporation Novel compositions and methods of treatment
KR101231466B1 (ko) 2004-09-13 2013-02-07 오노 야꾸힝 고교 가부시키가이샤 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는약제
CA2582324A1 (en) * 2004-10-01 2006-04-13 Merck & Co., Inc. Compositions and methods for treating ophthalmic diseases
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
JPWO2006129679A1 (ja) 2005-05-31 2009-01-08 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
US7799795B2 (en) 2005-06-27 2010-09-21 Amgen Inc. Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders
DE602006018176D1 (en) * 2005-09-26 2010-12-23 Merck Sharp & Dohme N-(4-oxo-3,4-dihydrochinazolin-2-yl)butanamide als androgenrezeptormodulatoren
CA2644368A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
CA2647391C (en) 2006-04-04 2015-12-29 The Regents Of The University Of California Kinase antagonists
DK2012789T3 (da) 2006-04-14 2013-12-16 Prana Biotechnology Ltd Fremgangsmåde til behandling af aldersrelateret makulær degeneration (AMD)
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
JP2009545317A (ja) * 2006-08-01 2009-12-24 アプライド バイオシステムズ, エルエルシー 分析物および核酸の検出
AU2007303846B2 (en) * 2006-10-04 2011-03-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists
US8273747B2 (en) 2006-11-02 2012-09-25 Curis, Inc. Small organic molecule regulators of cell proliferation
WO2008085828A2 (en) 2007-01-03 2008-07-17 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
KR101897881B1 (ko) 2008-01-04 2018-09-12 인텔리카인, 엘엘씨 특정 화학 물질, 조성물 및 방법
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
CN102124009B (zh) 2008-07-08 2014-07-23 因特利凯公司 激酶抑制剂及其使用方法
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
WO2010045542A2 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン, エルエルシー 複素環式化合物およびその使用
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
JP6027611B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ, インコーポレイテッド 複素環式化合物及びその使用
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
AU2012302197B2 (en) 2011-08-29 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
AU2013323426A1 (en) 2012-09-26 2015-04-23 The Regents Of The University Of California Modulation of ire1
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
JP6466924B2 (ja) 2013-10-04 2019-02-06 インフィニティー ファーマシューティカルズ, インコーポレイテッド 複素環式化合物及びその使用
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
DK3119397T3 (da) 2014-03-19 2022-03-28 Infinity Pharmaceuticals Inc Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
AR099789A1 (es) * 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20180058741A (ko) 2015-09-14 2018-06-01 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
US20230321063A1 (en) * 2020-08-20 2023-10-12 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Compositions and methods to reduce neuroinflammation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU729415B2 (en) 1996-07-12 2001-02-01 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US5919776A (en) 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US5948775A (en) 1997-03-19 1999-09-07 American Home Products Corporation 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones
EP1091960A1 (en) 1998-06-29 2001-04-18 The Regents Of The University Of California Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents
US6617115B1 (en) 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
MXPA02004162A (es) 1999-10-27 2003-08-20 Cytokinetics Inc Metodo y composiciones que utilizan quinazolinonas.

Similar Documents

Publication Publication Date Title
JP2003508388A5 (US07794700-20100914-C00152.png)
RU2324684C2 (ru) Пиримидиновые производные
JP2001515075A5 (US07794700-20100914-C00152.png)
RU2317294C2 (ru) (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора
JP2007537147A5 (US07794700-20100914-C00152.png)
JP2003523927A5 (US07794700-20100914-C00152.png)
JP2002536445A5 (US07794700-20100914-C00152.png)
JP2003519676A5 (US07794700-20100914-C00152.png)
JP2002541233A5 (US07794700-20100914-C00152.png)
JP2003522101A5 (US07794700-20100914-C00152.png)
JP2003501474A5 (US07794700-20100914-C00152.png)
JP2004534846A5 (US07794700-20100914-C00152.png)
RU2003116059A (ru) Арилэфирзамещенные имидазохинолины
RU2002120922A (ru) Нуклеозидные аналоги с карбоксамидин-модифицированным моноциклическим основанием
RU2001104339A (ru) Производные тиобензимидазола
JP2003500442A5 (US07794700-20100914-C00152.png)
RU2003107921A (ru) Селективные циклопептиды
JP2009536660A5 (US07794700-20100914-C00152.png)
RU2001135826A (ru) Новое применение соединений в качестве антибактериальных средств
RU97108698A (ru) Конъюгаты интерферона
RU2004134604A (ru) Тетрагидропиранилциклопентилтерагидропиридопиридиновые модуляторы активности рецептора хемокина
JP2001526218A5 (US07794700-20100914-C00152.png)
RU2004100302A (ru) Амиды антраниловой кислоты с гетероарилсульфонильной боковой цепью, способ их получения, их применение в качестве лекарственного или диагностического средства, а также содержащие их фармацевтические композиции
JP2002527414A5 (US07794700-20100914-C00152.png)
RU99101081A (ru) Режим введения ингибиторов н+, к+-атфазы